Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$27.51 USD
-0.55 (-1.96%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $27.51 0.00 (0.00%) 7:08 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Apellis Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 397 | 75 | 67 | 251 | 0 |
Cost Of Goods | 59 | 6 | 80 | 25 | 0 |
Gross Profit | 338 | 70 | -14 | 226 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 855 | 664 | 523 | 439 | 288 |
Income After Depreciation & Amortization | -517 | -595 | -536 | -214 | -288 |
Non-Operating Income | 20 | -24 | -196 | -99 | -11 |
Interest Expense | 30 | 33 | 13 | 30 | 5 |
Pretax Income | -527 | -652 | -746 | -343 | -305 |
Income Taxes | 2 | 1 | 0 | 2 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -529 | -652 | -746 | -345 | -305 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -529 | -652 | -746 | -345 | -305 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -489 | -593 | -534 | -198 | -285 |
Depreciation & Amortization (Cash Flow) | 28 | 2 | 2 | 16 | 3 |
Income After Depreciation & Amortization | -517 | -595 | -536 | -214 | -288 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 118.68 | 106.11 | 84.42 | 75.16 | 62.23 |
Diluted EPS Before Non-Recurring Items | -4.45 | -6.15 | -8.84 | -4.59 | -4.64 |
Diluted Net EPS (GAAP) | -4.45 | -6.15 | -8.84 | -4.59 | -4.90 |
Fiscal Year end for Apellis Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 199.69 | 172.33 | 146.38 | 110.40 | 94.97 |
Cost Of Goods | 23.10 | 20.21 | 19.91 | 22.41 | 8.38 |
Gross Profit | 176.59 | 152.12 | 126.47 | 87.99 | 86.59 |
SG&A, R&D, and Dept/Amort Expenses | 206.03 | 214.21 | 210.98 | 225.07 | 207.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | -29.44 | -62.09 | -84.51 | -137.08 | -120.44 |
Non-Operating Income | 1.26 | 2.80 | 4.77 | 4.39 | 5.94 |
Interest Expense | 9.36 | 6.97 | 7.40 | 7.31 | 7.34 |
Pretax Income | -37.54 | -66.25 | -87.15 | -140.00 | -121.84 |
Income Taxes | 0.11 | 0.17 | 1.42 | 0.23 | 0.19 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -37.66 | -66.42 | -88.58 | -140.24 | -122.04 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -37.66 | -66.42 | -88.58 | -140.24 | -122.04 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 123.90 | 122.96 | 121.23 | 120.29 | 119.32 |
Diluted EPS Before Non-Recurring Items | -0.28 | -0.54 | -0.73 | -1.17 | -1.02 |
Diluted Net EPS (GAAP) | -0.30 | -0.54 | -0.70 | -1.17 | -1.02 |